UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 19, 2015
Tribute Pharmaceuticals Canada Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Ontario, Canada | | 000-31198 | | Not Applicable |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
151 Steeles Avenue East, Milton, Ontario, Canada L9T 1Y1
(Address of principal executive offices) (Zip Code)
(519) 434-1540
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Tribute Pharmaceuticals Canada Inc.’s (the “Company”) 2015 annual and special meeting of shareholders will be held on Friday, June 19, 2015. The materials mailed by the Company to its shareholders on May 19, 2015 in connection with such meeting are filed under Item 9.01 herewith.
| Item 9.01. | Financial Statements and Exhibits. |
d) Exhibits
The following exhibits are filed herewith:
| | |
| 99.1 | | Notice of Annual and Special Meeting and Management Information Circular dated May 6, 2015 |
| 99.2 | | Notice-and-Access |
| 99.3 | | Voting Instruction Form |
| 99.4 | | Form of Proxy |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | TRIBUTE PHARMACEUTICALS CANADA INC. | |
| | | | |
| Date: May 21, 2015 | By: | /s/ Scott Langille | |
| | | Name: Scott Langille | |
| | | Title: Chief Financial Officer | |
| | | | |
EXHIBIT INDEX
| | |
| 99.1 | | Notice of Annual and Special Meeting and Management Information Circular dated May 6, 2015 |
| 99.2 | | Notice-and-Access |
| 99.3 | | Voting Instruction Form |
| 99.4 | | Form of Proxy |
